145 related articles for article (PubMed ID: 38850856)
1. DprE1 and Ddn as promising therapeutic targets in the development of novel anti-tuberculosis nitroaromatic drugs.
Paoli-Lombardo R; Primas N; Vanelle P
Eur J Med Chem; 2024 Aug; 274():116559. PubMed ID: 38850856
[TBL] [Abstract][Full Text] [Related]
2. Synthetic molecules as DprE1 inhibitors: A patent review.
Imran M; A S A; Thabet HK; Abida ; Afroz Bakht M
Expert Opin Ther Pat; 2021 Aug; 31(8):759-772. PubMed ID: 33709862
[TBL] [Abstract][Full Text] [Related]
3. Exploring the Potential Inhibition of Candidate Drug Molecules for Clinical Investigation Based on their Docking or Crystallographic Analyses against
Dey R; Nandi S; Samadder A; Saxena A; Saxena AK
Curr Top Med Chem; 2020; 20(29):2662-2680. PubMed ID: 32885754
[TBL] [Abstract][Full Text] [Related]
4. Decaprenylphosphoryl-β-D-ribose 2'-epimerase from Mycobacterium tuberculosis is a magic drug target.
Manina G; Pasca MR; Buroni S; De Rossi E; Riccardi G
Curr Med Chem; 2010; 17(27):3099-108. PubMed ID: 20629622
[TBL] [Abstract][Full Text] [Related]
5. Structure-activity relationship mediated molecular insights of DprE1 inhibitors: A Comprehensive Review.
Dash S; Rathi E; Kumar A; Chawla K; Joseph A; Kini SG
J Biomol Struct Dyn; 2024 Aug; 42(12):6472-6522. PubMed ID: 37395797
[TBL] [Abstract][Full Text] [Related]
6. Characterization of DprE1-Mediated Benzothiazinone Resistance in Mycobacterium tuberculosis.
Foo CS; Lechartier B; Kolly GS; Boy-Röttger S; Neres J; Rybniker J; Lupien A; Sala C; Piton J; Cole ST
Antimicrob Agents Chemother; 2016 Nov; 60(11):6451-6459. PubMed ID: 27527085
[TBL] [Abstract][Full Text] [Related]
7. Virtual Screening of Small Molecular Inhibitors against DprE1.
Zhang G; Guo S; Cui H; Qi J
Molecules; 2018 Feb; 23(3):. PubMed ID: 29495447
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in the development of DprE1 inhibitors using AI/CADD approaches.
Chen K; Xu R; Hu X; Li D; Hou T; Kang Y
Drug Discov Today; 2024 Jun; 29(6):103987. PubMed ID: 38670256
[TBL] [Abstract][Full Text] [Related]
9. Overview of the Development of DprE1 Inhibitors for Combating the Menace of Tuberculosis.
Chikhale RV; Barmade MA; Murumkar PR; Yadav MR
J Med Chem; 2018 Oct; 61(19):8563-8593. PubMed ID: 29851474
[TBL] [Abstract][Full Text] [Related]
10. Identification of a Chemical Inhibitor with a Novel Scaffold Targeting Decaprenylphosphoryl-β-D-Ribose Oxidase (DprE1).
Matsunaga T; Monobe K; Aoki S
Infect Disord Drug Targets; 2023; 23(5):e090323214508. PubMed ID: 36892121
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and evaluation of covalent inhibitors of DprE1 as antitubercular agents.
Liu L; Kong C; Fumagalli M; Savková K; Xu Y; Huszár S; Sammartino JC; Fan D; Chiarelli LR; Mikušová K; Sun Z; Qiao C
Eur J Med Chem; 2020 Dec; 208():112773. PubMed ID: 32898793
[TBL] [Abstract][Full Text] [Related]
12. Thiolates chemically induce redox activation of BTZ043 and related potent nitroaromatic anti-tuberculosis agents.
Tiwari R; Moraski GC; Krchňák V; Miller PA; Colon-Martinez M; Herrero E; Oliver AG; Miller MJ
J Am Chem Soc; 2013 Mar; 135(9):3539-49. PubMed ID: 23402278
[TBL] [Abstract][Full Text] [Related]
13. Identification of DprE1 inhibitors for tuberculosis through integrated in-silico approaches.
Dash S; Rathi E; Kumar A; Chawla K; Kini SG
Sci Rep; 2024 May; 14(1):11315. PubMed ID: 38760437
[TBL] [Abstract][Full Text] [Related]
14. Discovery of novel reversible inhibitor of DprE1 based on benzomorpholine for the treatment of tuberculosis.
Xiang W; He H; Duan X; He Z; Xu X; Liao M; Teng F; Li X; Luo T; Zeng J; Yu L; Gao C
Microbiol Spectr; 2023 Sep; 11(5):e0472122. PubMed ID: 37698416
[TBL] [Abstract][Full Text] [Related]
15. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
16. Optimization of Hydantoins as Potent Antimycobacterial Decaprenylphosphoryl-β-d-Ribose Oxidase (DprE1) Inhibitors.
Balabon O; Pitta E; Rogacki MK; Meiler E; Casanueva R; Guijarro L; Huss S; Lopez-Roman EM; Santos-Villarejo Á; Augustyns K; Ballell L; Aguirre DB; Bates RH; Cunningham F; Cacho M; Van der Veken P
J Med Chem; 2020 May; 63(10):5367-5386. PubMed ID: 32342688
[TBL] [Abstract][Full Text] [Related]
17. Nitroarenes as Antitubercular Agents: Stereoelectronic Modulation to Mitigate Mutagenicity.
Landge S; Ramachandran V; Kumar A; Neres J; Murugan K; Sadler C; Fellows MD; Humnabadkar V; Vachaspati P; Raichurkar A; Sharma S; Ravishankar S; Guptha S; Sambandamurthy VK; Balganesh TS; Ugarkar BG; Balasubramanian V; Bandodkar BS; Panda M
ChemMedChem; 2016 Feb; 11(3):331-9. PubMed ID: 26751718
[TBL] [Abstract][Full Text] [Related]
18. Current Affairs, Future Perspectives of Tuberculosis and Antitubercular Agents.
Gawad J; Bonde C
Indian J Tuberc; 2018 Jan; 65(1):15-22. PubMed ID: 29332642
[TBL] [Abstract][Full Text] [Related]
19. Bactericidal activity of PA-824 against Mycobacterium tuberculosis under anaerobic conditions and computational analysis of its novel analogues against mutant Ddn receptor.
Somasundaram S; Anand RS; Venkatesan P; Paramasivan CN
BMC Microbiol; 2013 Oct; 13():218. PubMed ID: 24083570
[TBL] [Abstract][Full Text] [Related]
20. Structure, dynamics, and interaction of Mycobacterium tuberculosis (Mtb) DprE1 and DprE2 examined by molecular modeling, simulation, and electrostatic studies.
Bhutani I; Loharch S; Gupta P; Madathil R; Parkesh R
PLoS One; 2015; 10(3):e0119771. PubMed ID: 25789990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
